Positive findings from Allergy Therapeutics' grass allergy vaccine testing
Allergy Therapeutics has revealed new data that shows its grass allergy vaccine is highly affective in reducing the effects of an allergic reaction to grass.
The Worthing-based biotech company said today that testing had revealed that field trials of its Grass MATA MPL product had performed highly in reducing symptoms and medication need in clinical trials with subjects enrolled across 13 sites in Germany and the US.
The announcement was made at the 2022 American Academy of Allergy Asthma and Immunology Annual Meeting held in Phoenix, Arizona.
READ MORE: South East life sciences: round-up of main stories in January
Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, said: "Demonstrating a nearly 40% reduction in combined symptom and medication score compared to placebo in a grass pollen allergy trial is a significant event in our history.
"We are very much looking forward to the pivotal G306 clinical trial of our Grass MATA MPL immunotherapy that is due to commence later this year and, if successful, would enable registration in Europe and the US.
"Such a product would permit patients suffering from grass pollen allergy the opportunity to address the cause of their disease, not just mask their symptoms."
Allergy Therapeutics peanut allergy vaccine, VLP Peanut, also performed well in clinical tests with the treatment found not to elicit an allergic reaction and a reduction in symptoms.
The company is also working on vaccines for allergies to tree and house dust mites and employs around 600 people.
Discover the best places to visit and stay in the South East of England >>
